Sentence: We investigated the maximum tolerated dose , dose-limiting toxicities , and response rate when the selective cyclooxygenase-2 inhibitor celecoxib is added to concurrent irinotecan , cisplatin , and radiation therapy for patients with inoperable stage II-III non-small cell lung cancer ( NSCLC ) .
Drug combination annotation:
[{'class': 'POS', 'spans': ['celecoxib', 'irinotecan', 'cisplatin'], 'is_context_needed': True}]